ライフサイエンスコーパス: patient receiving

1 the present study, 15 relapsing-remitting MS patients receiving 1,000 mg of rituximab were included.

2 mg upadacitinib (P < .1 vs placebo), 11% of patients receiving 12 mg upadacitinib, and 22% of patien

3 is study was to evaluate differences between patients receiving (18)F-fluciclovine and (68)Ga-prostat

4 om Australia, Canada, Italy and UK for adult patients receiving 2 L treatment for advanced/metastatic

5 Apixaban drug concentrations were lower in patients receiving 2.5 mg twice daily compared with 5 mg

6 Methods: Fourteen patients receiving (225)Ac-PSMA-I&T were included in thi

7 4 mg upadacitinib twice daily, and by 14% of patients receiving 24 mg upadacitinib once daily, vs 11%

8 nts receiving 12 mg upadacitinib, and 22% of patients receiving 24 mg upadacitinib twice daily, and b

9 y, clinical remission was achieved by 13% of patients receiving 3 mg upadacitinib, 27% of patients re

10 DERS FREE) reported superior outcomes of HBR patients receiving 30-day dual antiplatelet therapy afte

11 patients receiving 3 mg upadacitinib, 27% of patients receiving 6 mg upadacitinib (P < .1 vs placebo)

12 ients, and the XT was used in 22%, with most patients receiving a 29-mm (39%) or 26-mm (34%) valve.

13 In the study period from 2008 to 2019 all patients receiving a decompression tube were identified

14 ender difference in survival was noted among patients receiving a DNR order (6.7% versus 7.4%, P=0.90

15 RNFL thinning and number of injections among patients receiving a greater number of injections, sugge

16 This study included 2350 patients receiving a mite allergoid and 64 740 control p

17 blation rate was 69%, with better results in patients receiving a single administration of about 3.7

18 Among HCV patients, receiving a re-LT in the post-DAA era was asso

19 Patients receiving additional placement of cryopreserved

20 There was no improvement in PFS in patients receiving afatinib plus cetuximab compared with

21 ents related to treatment occurred in 72% of patients receiving afatinib plus cetuximab compared with

22 raft survival was significantly superior for patients receiving aggregation inhibitors after LT.

23 no worsening of NASH was achieved in 38% of patients receiving aldafermin vs 18% of patients receivi

24 V-DNA and HBV-RNA decreased from baseline in patients receiving all doses of JNJ-6379, independently

25 The adherence of patients receiving allergoid was 63.8% at the end of the

26 sulting in inhibition of treatment effect in patients receiving alteplase.

27 tenuation and LAI derived from TNC-images of patients receiving amiodarone were higher.

28 f OVP were given during the study, with each patient receiving an average of 12 doses.

29 ormed evaluating 4 contemporary ICD leads in patients receiving an ICD system for the first time.

30 CI myocarditis (cases, n = 101) to that from patients receiving an ICI who did not develop myocarditi

31 Patients receiving an intravascular microaxial LVAD were

32 enotype was also observed in prostate cancer patients receiving androgen deprivation therapy, highlig

33 s. 0.04% of cases), and occurred in 0.35% of patients receiving anterior vitrectomy.

34 Approximately 50% of patients receiving anti-vascular endothelial growth fact

35 However, patients receiving anti-VEGF had on average a greater nu

36 ld be given to glaucoma surgical planning in patients receiving anti-VEGF injections, especially in t

37 ings for the Medicare Part B program and for patients receiving anti-VEGF intravitreal injections.

38 Patients receiving anti-VEGF therapy secondary to eAMD i

39 ESRD and non-ESRD patients receiving antibiotics was 520.29/1000 and 296.4

40 were performed to identify the proportion of patients receiving antibiotics.

41 The survival benefit observed in patients receiving antifungal therapy implies that the p

42 Patients receiving any packing or stenting achieved bett

43 Of 61 patients receiving apheresis at enrollment, 16 discontin

44 Patients receiving apixaban 2.5 mg twice daily exhibited

45 assigned study treatment, and 34 (63%) of 54 patients receiving apomorphine sublingual film and 46 (8

46 mmon side-effect, reported in 17 (31%) of 54 patients receiving apomorphine sublingual film and in fo

47 se events were transient nausea (in 15 [28%] patients receiving apomorphine sublingual film), somnole

48 s highly representative and includes >75% of patients receiving ART in Switzerland.

49 onal burden did not have predictive value in patients receiving atezolizumab plus chemotherapy in the

50 ment biopsies from relapsed/refractory DLBCL patients receiving avadomide (NCT01421524).

51 ngs of increased all-cause mortality risk in patients receiving basal insulin, especially those with

52 %, respectively; P < .01), were higher among patients receiving bedaquiline versus delamanid.

53 Patients receiving best available therapy could cross ov

54 he lower risk of Parkinson's disease seen in patients receiving beta-adrenoceptor agonists is likely

55 Patients receiving beta-blockers or angiotensin-converti

56 .022) and 15.0% at 48 hours (p = 0.0001) for patients receiving bilateral stimulation after excluding

57 ngs may help physicians in the management of patients receiving biotherapies.

58 on tool to safely increase the proportion of patients receiving BL regimen.

59 ventilation-free days, and the proportion of patients receiving blood transfusion.

60 At end of treatment, 73.5% of patients receiving BOT 0.5 mg twice daily and 75% receiv

61 Four patients receiving BOT developed asymptomatic, low serum

62 ay 42 post-HCT was significantly lower among patients receiving brincidofovir (14.2%) compared with p

63 The cohort consisted of 92 patients receiving brincidofovir and 61 receiving placeb

64 hort study from an international registry of patients receiving care at experienced HCM centers.

65 that arise during 3 phases of management for patients receiving CD19-targeted CAR-T cells: pre CAR-T-

66 pairs of primary-recurrent GBM samples from patients receiving chemoradiotherapy with temozolomide a

67 ll survival was 68.5% (95% CI 66.4-70.6) for patients receiving chemotherapy, 61.1% (59.0-63.2) for p

68 mostly portable/bedside studies, with 87% of patients receiving chest radiographs.

69 s of one-sample proportions were done in all patients receiving CHOP or R-CHOP.

70 ome was associated with phosphorus levels in patients receiving chronic dialysis.

71 associated with a greater risk of death for patients receiving chronic dialysis.

72 Our cohort included 258,510 patients receiving chronic hemodialysis in 2005-2013.

73 derate to severe pruritus was more common in patients receiving cilofexor 100 mg (14%) than in those

74 MRI-PDFF of >=30% were experienced by 39% of patients receiving cilofexor 100 mg (P = 0.011 vs. place

75 At week 24, patients receiving cilofexor 100 mg had a median relativ

76 otections for research participants than for patients receiving clinical care.

77 man immunodeficiency virus (HIV) co-infected patients receiving combined antiretroviral therapy.

78 In patients receiving continuous renal replacement therapy

79 dy weight of gadobenate dimeglumine, with 19 patients receiving contrast material.

80 We identified a total of 373 patients receiving conventional cardiac monitoring and 1

81 aseline characteristics and outcomes between patients receiving conventional cardiac monitoring with

82 Among patients receiving conventionally fractionated radiother

83 000 USD gross savings in filter cost per 100-patient receiving CRRT.

84 The probability of patients receiving curative treatment and long-term surv

85 ne and molecular profiling of CD8 T cells of patients receiving DC vaccines expressing three full-len

86 Methods: In total, 49 patients receiving definitive chemoradiation for locally

87 h enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regi

88 g resistance were significantly higher among patients receiving delamanid versus bedaquiline (36% vs

89 The study excluded 1,083 patients receiving dialysis and 847 discharged on thiazi

90 ocioeconomic status to phosphorus control in patients receiving dialysis are unknown.

91 9%; 95% CI, -16.6% to -1.2%); and, excluding patients receiving dialysis at baseline, AKI occurred in

92 VID-19 infections and outcomes for all adult patients receiving dialysis in a large dialysis center.

93 der plasma of 28 503 randomly selected adult patients receiving dialysis in July, 2020, using a spike

94 Many patients receiving dialysis in the USA share the socioec

95 of venous thromboembolism in critically ill patients receiving different regimens of prophylactic an

96 Functional recovery was 7 days for patients receiving direct oral feeding compared with 8 d

97 ate of all-cause mortality, especially among patients receiving doses of 25% to <50% (HR, 0.67 [95% C

98 Among high-risk patients receiving drug-eluting stents, the antithrombot

99 The outcome in patients receiving durable MCS after ECLS remains limite

100 rval, 1.3 to 2.3; P < 0.001).Conclusions: In patients receiving ECMO for respiratory failure, a large

101 h and without bisulfite treatment from mCRPC patients receiving either abiraterone or enzalutamide in

102 Matched pairs of patients receiving either balanced with volatile anaesth

103 fference between other complication rates in patients receiving either oil viscosities.

104 Tremblay and colleagues asked whether patients receiving either routine anticoagulation or ant

105 We report a case series of adult patients receiving en-bloc heart-liver transplantation (

106 Retrospective review of patients receiving en-bloc HLTx over 18 months, with cli

107 We excluded patients receiving end-of-life care.

108 ce of a difference in favourable outcomes of patients receiving endovascular therapy compared with th

109 Endoscopic improvement occurred in 41.8% of patients receiving etrasimod 2 mg vs 17.8% receiving pla

110 Early extubation in select patients receiving extracorporeal carbon dioxide removal

111 Although acute brain injury is common in patients receiving extracorporeal membrane oxygenation,

112 ors for mortality in pregnant and peripartum patients receiving extracorporeal membrane oxygenation.

113 about the optimal ventilation strategies for patients receiving extracorporeal support but also regar

114 enon that has previously been observed in PD patients receiving fetal tissue grafts but has not been

115 tion had significantly worse OS and PFS than patients receiving first-line chemotherapy followed by r

116 health care databases were used to identify patients receiving first-line glaucoma therapy and to as

117 perience worse visual outcomes compared with patients receiving fixed, frequent therapy in randomized

118 Patients receiving fluticasone propionate <=500 mcg/day

119 reated with bisGMA-based materials and among patients receiving general anesthesia compared with pret

120 adverse events occurred in eight (3%) of 245 patients receiving guselkumab every 4 weeks (three serio

121 adverse events up to week 24 occurred in no patients receiving guselkumab every 4 weeks, four (3%) p

122 eceiving guselkumab every 4 weeks, four (3%) patients receiving guselkumab every 8 weeks, and five (4

123 Patients receiving HCV-viremic hearts were treated, assu

124 of aprepitant or fosaprepitant in pediatric patients receiving HEC or MEC.

125 cute-phase complete CIV control in pediatric patients receiving HEC or MEC.

126 ge) of 6 (0-52) acute attacks, with 52 (46%) patients receiving hemin prophylaxis.

127 ally fatal immune disorder affecting 1-5% of patients receiving heparin.

128 ities (~1.1 GBq) and lower rates (8%-18%) in patients receiving higher activities of radioiodine (~3.

129 diac arrest was significantly more likely in patients receiving hydroxychloroquine + azithromycin (ad

130 no significant differences in mortality for patients receiving hydroxychloroquine + azithromycin (HR

131 The probability of death for patients receiving hydroxychloroquine + azithromycin was

132 [CI], 0.81 to 1.11; P = 0.50), in 104 of 947 patients receiving hydroxychloroquine and in 84 of 906 r

133 Several studies found that patients receiving hydroxychloroquine developed a QTc in

134 of liver-enzyme levels were more frequent in patients receiving hydroxychloroquine, alone or with azi

135 Among patients receiving hypofractionated radiotherapy, younge

136 rogression-free and overall survival for all patients receiving I/T/DIN/GM-CSF were 67.9% +/- 6.4% (9

137 Finally, patients receiving ICI tended to have a longer median OS

138 Rates of ophthalmic immune-related AEs among patients receiving ICI therapy were higher compared with

139 y forecasting of ultimate outcomes for NSCLC patients receiving ICIs.

140 an important irAE, occurring in up to 16% of patients receiving ICIs.

141 Patients receiving ICM were also found to have significa

142 ving conventional cardiac monitoring and 123 patients receiving ICM.

143 The development of inflammatory arthritis in patients receiving immune checkpoint inhibitor therapy i

144 nobiology and as an independent biomarker in patients receiving immune-checkpoint inhibitors.

145 The increasing incidence of PML in patients receiving immunotherapeutic and chemotherapeuti

146 aluable tool for clinical decision making in patients receiving immunotherapy.

147 Specifically, among patients receiving Impella, there was a wide variation i

148 ads is essential to optimizing treatment for patients receiving implantable cardioverter-defibrillato

149 Patients receiving IMV were also compared with matched h

150 hitect system to test serum samples from 356 patients receiving in-center hemodialysis for SARS-CoV-2

151 al Data System registry data to identify all patients receiving in-center hemodialysis from 2006 thro

152 ly associated with all-cause mortality among patients receiving in-center hemodialysis.

153 h seroprevalence of SARS-CoV-2 antibodies in patients receiving in-center hemodialysis.

154 omic status and serum phosphorus level among patients receiving incident dialysis.

155 Among patients receiving initial treatment for symptomatic, pa

156 c fever in Bangladesh, with higher costs for patients receiving inpatient care.

157 Patients receiving insulin were randomised 1:1:1:1 to pl

158 0.79 to 1.25; P = 0.97), and in 243 of 2050 patients receiving interferon and in 216 of 2050 receivi

159 A third of patients receiving Interferon-alpha (IFN-alpha) treatmen

160 Patients receiving intracameral moxifloxacin showed appr

161 The proportion of patients receiving intravenous thrombolysis with door-to

162 entre for Ophthalmic Studies (BPKLCOS) among patients receiving intravitreal bevacizumab.

163 hese results, the 90-day rate of RRD in nAMD patients receiving intravitreal injections is low.

164 ower than that in the usual care group among patients receiving invasive mechanical ventilation (29.3

165 adverse events grade >= 3 occurred in 37% of patients receiving ipi3, 79% receiving HDI, and 58% rece

166 The incidence of bIFIs in patients receiving ISA was compared to those receiving p

167 t differences in neurocognitive outcomes for patients receiving IT MTX compared with ITT.

168 relapse rates, or in toxicities observed for patients receiving IT MTX compared with ITT.

169 ter initiation of treatment when compared to patients receiving itraconazole (HR 4.30 [95% CI 1.3-13.

170 nd lactate measurements taken, percentage of patients receiving IV fluids, and appropriate initial an

171 Two LGI1-IgG-seropositive patients receiving IVIG, but none receiving placebo, wer

172 erse events were reported in 36 (30%) of 121 patients receiving ivosidenib and 13 (22%) of 59 patient

173 ients receiving placebo and nine [7%] of 121 patients receiving ivosidenib).

174 n adverse event was constipation (in 8.1% of patients receiving IW-3718 and 7.1% of patients receivin

175 ective, observational study, we analyzed all patients receiving kidney-alone transplants between 2003

176 In ALL patients receiving L-ASP therapy, the use of fibrinogen

177 More patients receiving lanadelumab vs placebo were attack fr

178 In patients receiving LD grafts, the expression of most gen

179 CI, 0.89 to 1.59; P = 0.23), in 148 of 1399 patients receiving lopinavir and in 146 of 1372 receivin

180 -24% of patients, with higher rates (24%) in patients receiving low radioiodine activities (~1.1 GBq)

181 Patients receiving LT) for HCC are at a high risk for tu

182 Relative to no cisplatin exposure, patients receiving < 200 mg/m(2) were not at greater ris

183 ional outcome, however, did not differ among patients receiving mechanical adjuvant or not.

184 mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between

185 as 15% (95% CI, 4-34%), and the mortality of patients receiving mechanical ventilation was 19% (95% C

186 atients with active opioid use disorder, and patients receiving medication for opioid use disorder.

187 Patients receiving mixed care were also analyzed based o

188 Conclusion: In patients receiving molecular imaging for prostate cancer

189 rbidities and was observed selectively among patients receiving more intensive conditioning, includin

190 ions: Raised pleural suPAR was predictive of patients receiving more invasive management of parapneum

191 All measured outcomes did not differ in patients receiving MPP-AS and biventricular single-site

192 Conclusion In patients receiving multiple doses of gadobenate dimeglum

193 ric regimens is likely to lead to more adult patients receiving multiple doses of pegasparaginase.

194 aphics of the unmatched cohort revealed that patients receiving NCRS were younger, had a lower burden

195 In logistic models, compared with patients receiving neither drug cardiac arrest was signi

196 x proportional hazards models, compared with patients receiving neither drug, there were no significa

197 l with COVID-19 have different outcomes from patients receiving neither therapy.

198 Of the patients receiving NGM282 1 mg or 3 mg, 25% and 42%, res

199 of T and NK cells in the peripheral blood of patients receiving NKTR-214 in a phase 1 trial.

200 OS was significantly better than in HCC-PVTT patients receiving no intervention or palliative Sorafen

201 treated with cytokine inhibitors compared to patients receiving no such inhibitors and two healthy co

202 Patients receiving Ologen-augmented AGV surgery exhibite

203 sea, and fatigue were also more common among patients receiving omaveloxolone.

204 on HCV prevalence and incidence rates among patients receiving opioid substitution treatment (OST) a

205 In patients receiving OPT-302 monotherapy, 7 of 13 (54%) di

206 nations (DFEs) were assessed for established patients receiving optical coherence tomography (OCT)-gu

207 dine 35 mg twice daily over several years in patients receiving optimal medical therapy, after succes

208 One patient receiving oral RBV had to prematurely stop drug

209 We assess the cardiac failure risk in patients receiving osimertinib by evaluating the availab

210 ern that was suggestive of a safety issue in patients receiving osimertinib.

211 roke, or non-fatal myocardial infarction) in patients receiving PCI or CABG.

212 In patients receiving pegcetacoplan monthly or EOM, the GA

213 diagnostic yield and increase the number of patients receiving personalized care and counselling on

214 Six studies evaluated patients receiving PhMT-b via corticotomy-assisted ortho

215 % of patients receiving aldafermin vs 18% of patients receiving placebo (P = .10).

216 For masking purposes, patients receiving placebo also received two injections

217 reatment groups was ascites (four [7%] of 59 patients receiving placebo and nine [7%] of 121 patients

218 1% of patients receiving IW-3718 and 7.1% of patients receiving placebo).

219 phine sublingual film and in four (7%) of 55 patients receiving placebo, leading to treatment discont

220 Compared with patients receiving placebo, patients treated with recomb

221 Compared with patients receiving placebo, those receiving ziltivekimab

222 CI: 0.8 to 18.8 U) stimuli were higher among patients receiving placebo, whereas levels of platelet r

223 ed in 59% receiving pembrolizumab and 38% of patients receiving placebo.

224 fter endovascular thrombectomy compared with patients receiving placebo.

225 g upadacitinib, respectively, vs none of the patients receiving placebo.

226 ing 24 mg upadacitinib once daily, vs 11% of patients receiving placebo.

227 ents receiving ivosidenib and 13 (22%) of 59 patients receiving placebo.

228 ving guselkumab every 8 weeks, and five (4%) patients receiving placebo.

229 Cancer InterGroup (GCIG) CA125 responses in patients receiving platinum-based neoadjuvant chemothera

230 Recurrence was similar in patients receiving PMRT compared to those that did not:

231 Comparisons were made among patients receiving pre-LT LRT with (n = 802) and without

232 s, although arrhythmic risk was higher among patients receiving primary prevention implantable cardio

233 Rationale: Patients receiving prolonged mechanical ventilation expe

234 es that may be helpful in improving care for patients receiving prolonged mechanical ventilation.

235 entify a set of effective care practices for patients receiving prolonged mechanical ventilation.Meth

236 (18)F-FDG-positive patients receiving PRRT had a significantly longer media

237 All patients receiving PRRT using the fast-infusion protocol

238 For patients receiving PRRT, (18)F-FDG-negative cases had a

239 Patients receiving ranibizumab were older (mean differen

240 13%) patients receiving RS8 and in nine (7%) patients receiving RC8.

241 Hospitalized patients receiving RDV for COVID-19 between 5/1/2020-10/

242 ebound congestion, in limited circumstances, patients receiving regimens that include an INCS may be

243 onths, we found higher primary patency among patients receiving regional versus local anesthesia (50

244 -VEGF treatment, with a control group of DME patients receiving regular anti-VEGF treatment without l

245 Death occurred in 301 of 2743 patients receiving remdesivir and in 303 of 2708 receivi

246 Although not statistically significant, patients receiving remdesivir had a numerically faster t

247 Compared with controls, fewer patients receiving remote ischemic preconditioning devel

248 oprotectants in enriched clinical studies of patients receiving reperfusion therapies, might prove mo

249 Myocardial infarction patients receiving reperfusion therapy show magnetic sus

250 hepatitis B surface antigen (HBsAg)-positive patients receiving rituximab-based B-cell depletion ther

251 adverse events were grade 1-2, but one (1%) patient receiving RS8 developed serious ototoxicity and

252 ted adverse events were recorded in 20 (13%) patients receiving RS8 and in nine (7%) patients receivi

253 Anaemia was the most common adverse event in patients receiving ruxolitinib (rates per 100 patient-ye

254 At day 28, 24 (55.8%) of 43 patients receiving ruxolitinib and corticosteroids had a

255 Patients receiving RYGB met international guidelines for

256 Subset analyses compared patients receiving SALV after DCR with NCRS.

257 otocol-defined relapses occurred in 19 (30%) patients receiving satralizumab and 16 (50%) receiving p

258 3.7% of patients receiving TAVR and 16.4% of patients receiving SAVR at 1 year by using both trial da

259 component of the outcome was also higher in patients receiving SE-THV: >= moderate paravalvular regu

260 Patients receiving second-line chemotherapy followed by

261 We evaluated clinical outcomes of patients receiving shorter (5-9 days) versus longer (10-

262 Patients receiving single implant in a tooth-bound maxil

263 e care interventions were unit-percentage of patients receiving skin assessment on admission, receivi

264 reated with cooling anesthesia versus 44% of patients receiving SOC.

265 a sensitive marker of cardiac toxicity among patients receiving standard chemotherapy.

266 maH2AX & p16 nuclei in adipose tissue of OSA patients receiving statin, aspirin, and/or RAS inhibitor

267 Consistently, PDACs in patients receiving statins show enhanced mesenchymal fea

268 More patients receiving stenting developed postoperative gran

269 atherosclerosis, hypertension, as well as in patients receiving steroids before and during the operat

270 Notably, in patients receiving study drugs as second-line therapy, t

271 Here, we present 2 patients receiving such combination or sequential therap

272 ome was characterized in an acutely infected patient receiving supportive care alone to elucidate vir

273 The proportion of prescriptions for patients receiving surgery, emergency, and dental care i

274 Specimens from IU-CRLM patients receiving systemic/HAI chemotherapy (2003-2017)

275 zation was 20.3 (95% CI, 15.2 to 26.7) among patients receiving TAF/FTC, 10.5 (CI, 5.6 to 17.9) among

276 shear stress dependent and downregulated in patients receiving TAVI.

277 of all-cause mortality occurred in 13.7% of patients receiving TAVR and 16.4% of patients receiving

278 No patient receiving TDF/FTC was admitted to the ICU or die

279 HIV-positive patients receiving TDF/FTC have a lower risk for COVID-1

280 Dose reductions were more common in patients receiving the combination, and 30% of patients

281 Patients receiving the correct dose of study drug were i

282 rmite Europeene mark clinical information on patients receiving the HeartWare ventricular assist devi

283 Six out of 7 patients receiving the highest doses achieved CR and CR

284 However, in KALT patients receiving the matched-pair kidneys of the KTA r

285 In patients receiving the optimized ICG injection, there wa

286 ary end point, P<0.0001, with 50% (18/36) of patients receiving the protocol being explanted within 1

287 When only studies of patients receiving the same treatment(s) were compared,

288 early validation clinical data consisting of patients receiving therapy for liver metastases.

289 e of antifungal therapy (Mortality: 38.5% in patients receiving therapy versus 90% in patients not re

290 We analyzed 81 patients receiving these venetoclax-based combinations t

291 Patients receiving tradipitant had a significant decreas

292 Lesions were visualized early in patients receiving treatment, with SUV ranging from 5.85

293 refore an attractive adjunctive strategy for patients receiving Treg cell therapeutics.

294 kable in the inflammatory subsets of the SSc patients receiving TyKI therapy.

295 Implementation also led to a decrease in patients receiving unnecessary care.

296 pients, compared to 73%, 82.7%, and 81.2% in patients receiving unperfused DBD or DCD livers, from bo

297 vs placebo), and 14% (P < .05 vs placebo) of patients receiving upadacitinib, respectively, vs none o

298 have been implemented as standard of care in patients receiving venetoclax to minimise the risk of bo

299 DI criteria by 4 severity scoring methods in patients receiving versus not receiving laxatives (66.2%

300 l injury for high-risk populations (that is, patients receiving workers' compensation benefits, Veter